Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
982 DKK | -0.65% | +4.89% | +40.67% |
Jun. 11 | Health Care Down as Rally Pauses -- Health Care Roundup | DJ |
Jun. 11 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 42.25 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+40.67% | 631B | B | ||
+48.53% | 779B | C+ | ||
-6.37% | 354B | C+ | ||
+20.93% | 333B | B- | ||
+8.21% | 301B | C+ | ||
+16.75% | 249B | B+ | ||
-1.19% | 216B | A+ | ||
+10.85% | 214B | B- | ||
+4.40% | 163B | C+ | ||
-2.64% | 159B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- NOVO B Stock
- Ratings Novo Nordisk A/S